A Phase 2b study of Dalcinonacog-alfa (CB 2679d) in individuals with severe hemophilia B
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2018
At a glance
- Drugs Dalcinonacog alfa (Primary)
- Indications Haemophilia B
- Focus Therapeutic Use
- 18 Dec 2018 According to a Catalyst Biosciences media release, the company expects to initiate this trial in the first quarter of 2019.
- 28 Feb 2018 New trial record
- 26 Feb 2018 According to a Catalyst Biosciences media release, this trial is expected to begin in the third quarter of 2018.